Home About us Contact
|
Home About us Contact | ||
|
|
||
Histologic Observations (histologic + observation)
Selected AbstractsSystemic tetracycline delays degradation of three different collagen membranes in rat calvariaCLINICAL ORAL IMPLANTS RESEARCH, Issue 2 2009Ofer Moses Abstract Objectives: The aim of this study was to quantitatively evaluate the effect of systemic tetracycline (TTC) on the degradation of three different collagen membranes. Materials and methods: Collagen membranes were cut into 5 mm diameter membrane discs and labeled with aminohexanoyl-biotin- N -hydroxy-succinimide ester. One membrane disc each of a non-cross-linked [BioGide® (BG)], glutaraldehyde cross-linked [BioMend Extend® (BM)], and ribose cross-linked [OssixÔ (OS)] was implanted on the calvaria of 40 Wistar rats. Another 10 biotinylated collagen membrane discs from each membrane type were processed for histologic observation and served as baseline; half of them (five from each group) were also treated with formic acid to inspect possible interference with biotinilazation of collagen by formic acid used during the decalcification process. A 10 mg/kg dose of TTC (50% of the minimal recommended antibacterial dose) to the experimental (20 animals) and saline to the control (20 animals) group was administered intramuscularly every 3 days. From each group, block sections were retrieved in half of the animals after 14 days and in the remaining after 28 days. Decalcified tissue histology was stained with streptavidin horseradish peroxidase. A computer-assisted program measured the membranes' collagen contents. Statistical analysis consisted of analysis of variance (ANOVA) with repeated measures. Results: No statistically significant differences in collagen contents were appreciated between biotinylated non-implanted membranes treated or not treated by formic acid. Systemic TTC had a different effect on the bio-degradation of the membranes: while it significantly decreased the resorption of two of the membranes (BG and BM), it had minimal influence on the ribose cross-linked membrane (OS). ANOVA with repeated measures, tests of within-subjects effects, showed a statistically significant difference between the membranes (P<0.001), within the membranes at the different time-points (P<0.001), a significant interaction between membranes and time and between the membranes and administered TTC (P<0.001). Test of between-subject effects revealed a statistically significant interaction with time and with TTC (P<0.001). Conclusions: Systemically administered TTC in sub-antibacterial doses may offer a possible treatment alternative to reduce bio-degradation and enhance bio-durability of certain collagen membranes. The findings of the present study could have clinical application in large non-self-contained bone defects, where prolonged membrane barrier functions are desirable. [source] Alveolar ridge augmentation using implants coated with recombinant human growth/differentiation factor-5: histologic observationsJOURNAL OF CLINICAL PERIODONTOLOGY, Issue 8 2010Giuseppe Polimeni Polimeni G, Wikesjö UME, Susin C, Qahash M, Shanaman RH, Prasad HS, Rohrer MD, Hall J. Alveolar ridge augmentation using implants coated with recombinant human growth/differentiation factor-5: histologic observations. J Clin Periodontol 2010; 37: 759-768 doi: 10.1111/j.1600-051X.2010.01579.x. Abstract Objectives: In vitro and in vivo preclinical studies suggest that growth/differentiation factor-5 (GDF-5) may induce local bone formation. The objective of this study was to evaluate the potential of recombinant human GDF-5 (rhGDF-5) coated onto an oral implant with a purpose-designed titanium porous oxide surface to stimulate local bone formation including osseointegration and vertical augmentation of the alveolar ridge. Materials and Methods: Bilateral, critical-size, 5 mm, supraalveolar peri-implant defects were created in 12 young adult Hound Labrador mongrel dogs. Six animals received implants coated with 30 or 60 ,g rhGDF-5, and six animals received implants coated with 120 ,g rhGDF-5 or left uncoated (control). Treatments were alternated between jaw quadrants. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants for primary intention healing. The animals received fluorescent bone markers at weeks 3, 4, 7, and 8 post-surgery when they were euthanized for histologic evaluation. Results: The clinical examination showed no noteworthy differences between implants coated with rhGDF-5. The cover screw and implant body were visible/palpable through the alveolar mucosa for both rhGDF-5-coated and control implants. There was a small increase in induced bone height for implants coated with rhGDF-5 compared with the control, induced bone height averaging (±SD) 1.6±0.6 mm for implants coated with 120 ,g rhGDF-5 versus 1.2±0.5, 1.2±0.6, and 0.6±0.2 mm for implants coated with 60 ,g rhGDF-5, 30 ,g rhGDF-5, or left uncoated, respectively (p<0.05). Bone formation was predominant at the lingual aspect of the implants. Narrow yellow and orange fluorescent markers throughout the newly formed bone indicate relatively slow new bone formation within 3,4 weeks. Implants coated with rhGDF-5 displayed limited peri-implant bone remodelling in the resident bone; the 120 ,g dose exhibiting more advanced remodelling than the 60 and 30 ,g doses. All treatment groups exhibited clinically relevant osseointegration. Conclusions: rhGDF-5-coated oral implants display a dose-dependent osteoinductive and/or osteoconductive effect, bone formation apparently benefiting from local factors. Application of rhGDF-5 appears to be safe as it is associated with limited, if any, adverse effects. [source] Ex vivo bone morphogenetic protein-2 gene delivery using gingival fibroblasts promotes bone regeneration in ratsJOURNAL OF CLINICAL PERIODONTOLOGY, Issue 3 2010Joong-Ho Shin Shin J-H, Kim K-H, Kim S-H, Koo K-T, Kim T-I, Seol Y-J, Ku Y, Rhyu I-C, Chung C-P, Lee Y-M. Ex vivo bone morphogenetic protein-2 gene delivery using gingival fibroblasts promotes bone regeneration in rats. J Clin Periodontol 2009; 37: 305,311. doi: 10.1111/j.1600-051X.2009.01522.x. Abstract Aim: The aim of the present study was to investigate bone regeneration following ex vivo bone morphogenetic protein-2 (BMP-2) gene delivery using human gingival fibroblasts (HGFs) in rat calvarial defects. Materials and Methods: An 8 mm craniotomy defect was created in Sprague,Dawley rats. The animals were divided into four groups: (1) non-grafted group, the defect was left empty; (2) collagen matrix group, the defect was filled with collagen matrix only; (3) HGF group, the defect was filled with non-transduced HGFs on collagen matrix; (4) BMP-2/HGF group, the defect was filled with BMP-2 gene-transduced HGFs on collagen matrix. Animals were sacrificed at 2 and 4 weeks after surgery, and micro-computed tomographic and histologic observations were performed. Results: The BMP-2/HGF group showed promoted osseous healing of calvarial defects, as compared with the other groups. At both 2 and 4 weeks, regenerated bone area was significantly greater in the BMP-2/HGF group than the other three groups. Quite a few number of transplanted HGFs were observed within the regenerated bone tissues. Conclusions: The results of this study suggest that ex vivo BMP-2 gene delivery induces prominent bone regeneration in vivo and HGFs may be useful as target cells for ex vivo gene therapy. [source] Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: histologic observationsJOURNAL OF CLINICAL PERIODONTOLOGY, Issue 11 2008Ulf M. E. Wikesjö Abstract Background: Studies using ectopic rodent, orthotopic canine, and non-human primate models show that bone morphogenetic proteins (BMPs) coated onto titanium surfaces induce local bone formation. The objective of this study was to examine the ability of recombinant human BMP-2 (rhBMP-2) coated onto a titanium porous oxide implant surface to stimulate local bone formation including osseointegration and vertical augmentation of the alveolar ridge. Material and Methods: Bilateral, critical-size, 5 mm, supra-alveolar, peri-implant defects were created in 12 young adult Hound Labrador mongrel dogs. Six animals received implants coated with rhBMP-2 at 0.75 or 1.5 mg/ml, and six animals received implants coated with rhBMP-2 at 3.0 mg/ml or uncoated control. Treatments were randomized between jaw quadrants. The mucoperiosteal flaps were advanced, adapted and sutured to submerge the implants for primary intention healing. The animals received fluorescent bone markers at weeks 3, 4, 7 and 8 post-surgery when they were euthanized for histologic evaluation. Results: Jaw quadrants receiving implants coated with rhBMP-2 exhibited gradually regressing swelling that became hard to palpate disguising the contours of the implants. The histologic evaluation showed robust bone formation reaching or exceeding the implant platform. The newly formed bone exhibited characteristics of the adjoining resident Type II bone including cortex formation for sites receiving implants coated with rhBMP-2 at 0.75 or 1.5 mg/ml. Sites receiving implants coated with rhBMP-2 at 3.0 mg/ml exhibited more immature trabecular bone formation, seroma formation and peri-implant bone remodelling resulting in undesirable implant displacement. Control implants exhibited minimal, if any, bone formation. Thus, implants coated with rhBMP-2 at 0.75, 1.5 and 3.0 mg/ml exhibited significant bone formation (height and area) compared with the sham-surgery control averaging (±SD) 4.4±0.4, 4.2±0.7 and 4.2±1.2 versus 0.8±0.3 mm; and 5.0±2.2, 5.6±2.2 and 7.4±3.5 versus 0.7±0.3 mm2, respectively (p<0.01). All the treatment groups exhibited clinically relevant osseointegration. Conclusions: rhBMP-2 coated onto titanium porous oxide implant surfaces induced clinically relevant local bone formation including vertical augmentation of the alveolar ridge and osseointegration. Higher concentrations/doses were associated with untoward effects. [source] Polymer-assisted regeneration therapy with Atrisorb® barriers in human periodontal intrabony defectsJOURNAL OF CLINICAL PERIODONTOLOGY, Issue 1 2004Lein-Tuan Hou Abstract Aim: This study compared clinical results of 40 periodontal osseous defects treated by two types of absorbable barrier materials. Material and Methods: Thirty patients (23 males and seven females) suffering from moderate to advanced periodontitis (with comparable osseous defects) were randomly assigned to receive either Atrisorb® barrier (n=22; group A) or Resolut XT® barrier (n=18; group B) therapy. Periodontal phase I treatment and oral hygiene instruction were performed before periodontal surgery. Papillary preservation, partial thickness flap, citric acid root conditioning, and decortication procedures were applied during the operation. Bone defects were filled with demineralized freeze-dried bone allograft and minocycline mixture (4:1 ratio). Postoperative care included 0.10% chlorhexidine rinse daily and antibiotic medication for 2 weeks. Clinical assessments including probing depth (PD), clinical attachment level (CAL), gingival recession (GR), plaque index (PlI), gingival index (GI), and radiographic examinations were taken at the baseline, preoperatively and at 3 and 6 months after regenerative surgery. Results: Six months following therapy, both Atrisorb® and Resolut XT® groups had achieved comparable clinical improvement in pocket reduction (3.9 versus 4.4 mm), attachment tissue gain (clinical attachment gain; 3.5 versus 3.6 mm), and reduction in the GI and in the PlI. Within-group comparisons showed significant attachment gain and pocket reduction between baseline data and those at both 3 and 6 months postoperatively (p<0.01). There were no statistically significant differences in any measured data between groups A and B. Conclusions: The results of this study indicate that a comparable and favorable regeneration of periodontal defects can be achieved with both Atrisorb® and Resolut XT® barriers. Further long-term study and histologic observations of tissue healing are needed to evaluate whether Atrisorb® is promising for clinical use. [source] Periodontal repair in dogs: space-providing ePTFE devices increase rhBMP-2/ACS-induced bone formationJOURNAL OF CLINICAL PERIODONTOLOGY, Issue 8 2003Ulf M.E. Wikesjö Abstract Background: Recombinant human bone morphogenetic protein-2 (rhBMP-2) technologies have been shown to enhance alveolar bone formation significantly. Biomaterial (carrier) limitations, however, have restricted their biologic potential for indications where compressive forces may limit the volume of bone formed. The objective of this proof-of-principle study was to evaluate the potential of a space-providing, macroporous ePTFE device to define rhBMP-2-induced alveolar bone formation using a discriminating onlay defect model. Methods: Routine, critical size, 5,6 mm, supra-alveolar, periodontal defects were created around the third and fourth mandibular premolar teeth in four young adult Hound Labrador mongrel dogs. All jaw quadrants received rhBMP-2 (0.4 mg) in an absorbable collagen sponge (ACS) carrier. Contralateral jaw quadrants in subsequent animals were randomly assigned to receive additionally the dome-shaped, macroporous ePTFE device over the rhBMP-2/ACS implant or no additional treatment. The gingival flaps were advanced to cover the ePTFE device and teeth, and sutured. Animals were scheduled for euthanasia to provide for histologic observations of healing at 8 weeks postsurgery. Results: Healing was uneventful without device exposures. New bone formation averaged (±SD) 4.7±0.2 mm (98%) and 4.5±0.4 mm (94%) of the defect height, respectively, for jaw quadrants receiving rhBMP-2/ACS with the ePTFE device or rhBMP-2/ACS alone (p>0.05). In contrast, the regenerated bone area was significantly enhanced in jaw quadrants receiving rhBMP-2/ACS with the ePTFE device compared to rhBMP-2/ACS alone (9.3±2.7 versus 5.1±1.1 mm2; p<0.05). Cementum formation was similar for both treatment groups. Ankylosis compromised periodontal regeneration in all sites. Conclusions: The results suggest that the novel space-providing, macroporous ePTFE device appears suitable as a template to define rhBMP-2/ACS-induced alveolar bone formation. Zusammenfassung Hintergrund: Es wurde gezeigt, dass das rekombinante menschliche knochenmorphogenetische Protein 2 (rhBMP-2) die alveoläre Knochenbildung signifikant erhöht. Limitationen des Biomaterials (Träger) haben jedoch die biologischen Potenzen des Materials für die Indikationen, wo komprimierende Kräfte das Volumen des zu bildenden Knochen limitierten, eingeengt. Das Ziel dieser prinzipiellen geprüften Studie war die Evaluation der Platzhalterfunktion einer makroporösen e-PTFE Membran, um die von rhBMP-2 induzierten Knochenbildung unter Nutzung eines differenzierenden Onlaydefektmodells zu definieren. Methoden: Routinemäßig wurden supraalveoläre parodontale Defekte mit der kritischen Größe von 5,6 mm um die dritten und vierten Prämolaren bei 4 jungen adulten Labrodormischhunden geschaffen. Alle Quadranten erhielten rhBMP-2 (0.4 mg) in einem resorbierbaren Kollagenschwamm (ACS). Kontralaterale Quadranten bei den aufeinander folgenden Tieren wurden zufällig ausgewählt, um zusätzlich eine domförmige makroporöse e-PTFE Membran über das rhBMP-2/ACS Implantat oder keine zusätzliche Therapie zu erhalten. Die gingivalen Lappen wurden so präpariert, dass sie die e-PTFE Membran und Zähne bedeckten und vernäht. Die Tiere wurden 8 Wochen nach der Operation getötet und für histologische Untersuchungen vorbereitet. Ergebnisse: Die Heilung war komplikationslos ohne Exposition der Membran. Die neue Knochenbildung betrug durchschnittlich (±SD) 4.7±0.2 mm (98%) und 4.5±0.4 mm (94%) der Defekthöhe für die Quadranten, die rhBMP-2/ACS mit der e-PTFE Membran erhielten oder rhBMP-2/ACS allein (p>0,05). Im Kontrast dazu war das regenerierte Knochenfeld signifikant erweitert bei den Kieferquadranten, die rhBMP-2/ACS mit e-PTFE Membran erhielten im Vergleich zu denjenigen mit rhBMP-2/ACS allein (9.3±2.7 vs. 5.1±1.1 mm2; p<0.05). Die Zementbildung war in beiden Behandlungsgruppen ähnlich. Ankylosen gefährdeten die parodontalen Regeneration in allen Flächen. Schlussfolgerungen: Die Ergebnisse zeigen, dass die neue makroporöse Platzhalter e-PTFE Membran als Schablone nützlich ist, um die rhBMP-2/ACS induzierte alveoläre Knochenbildung zu betonen. Résumé Contexte: Des technologies utilisant la protéine-2 osseuse morphogénétique humaine recombinée (rhBMP-2) ont montré qu'elle permettait d'augmenter significativement la formation d'os alvéolaire. Les limites du biomatériel (vecteur), cependant, ont restreint leur potentiel biologique aux indications pour lesquels des forces compressives pourraient limiter le volume d'os en formation. L'objectif de cette étude fut d'évaluer le potentiel d'un dispositif en ePTFE macro-poreux permettant de créer un espace pour définir la formation d'os alvéolaire induit par la rhBMP-2 en utilisant un modèle discriminatoire de lésion. Méthodes: Des lésions parodontales supra-alvéolaires de taille critique, 5,6 mm, furent créées autour des troisièmes et quatrièmes prémolaires chez 4 Labrador adultes. Chaque quadrant a été traité par des éponges de collagène résorbables utilisé comme vecteur (ASC) contenant rhBMP-2 (0.4 mg). Les quadrants contralatéraux des animaux furent aléatoirement distribués pour recevoir (ou pas) en plus un dispositif macro-poreux en ePTFE, en forme de dôme sur les implants de rhBMP-2/ACS. Les lambeaux furent déplacés pour recouvrir le dispositif en ePTFE et les dents et suturés. Les animaux furent sacrifiés après 8 semaines pour fournir des observations histologiques de la cicatrisation. Résultats: La cicatrisation ne posait pas de problèmes et on ne nota pas d'exposition des dispositifs. La moyenne de la formation osseuse était de (±SD) 4.7±0.2 mm (98%) et 4.5±0.4 mm (94%) de la hauteur de la lésion, respectivement, pour les quadrants ayant été traités par la rhBMP-2/ACS avec le dispositif en ePTFE ou la rhBMP-2/ACS seule (p>0.05). A l'inverse, la surface osseuse régénérée était significativement plus importante dans les quadrants traités par la rhBMP-2/ACS et les dispositifs en ePTFE par rapport au site traités seulement par la rhBMP-2/ACS (9.3±2.7 vs. 5.1±1.1 mm2; p<0.05). La formation cémentaire était similaire pour les deux groupes de traitement. L'ankylose compromettait la régénération parodontale dans tous les sites. Conclusions: Ces résultats suggèrent que le dispositif en ePTFE macro-poreux, qui assure un espace, semble convenir comme standard pour définir la formation osseuse induite par la rhBMP-2/ACS. [source] | ||||||||||